T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test a combined therapy approach (allogeneic
cytomegalovirus [CMV]-specific T cells and pembrolizumab) in patients with brain cancer. The
type of brain cancer being studied is glioblastoma multiforme/astrocytoma grade 4.
The purpose of part 1 of this study is to determine the maximum-tolerated dose and/or
recommended dose(s) for future exploration of allogeneic CMV-specific T cells as monotherapy
or in combination with pembrolizumab in patients with recurrent GBM/astrocytoma grade 4. Part
2 of the study aims to investigate the anti-tumour activity of allogeneic CMV-specific T
cells as monotherapy or in combination with pembrolizumab, assessed by magnetic resonance
imaging and survival, in patients with recurrent or newly diagnosed GBM/grade 4 astrocytoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Queensland Institute of Medical Research
Collaborators:
Austin Hospital, Melbourne Australia CUREator Merck Sharp & Dohme LLC Princess Alexandra Hospital, Brisbane, Australia Royal Brisbane and Women's Hospital The Newro Foundation